{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.18","value":"0.44"},{"groupId":"OG001","spread":"12.75","value":"0.92"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"188"},{"groupId":"OG001","value":"200"}],"units":"Participants"}],"title":"Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.34","value":"-2.22"},{"groupId":"OG001","spread":"13.69","value":"-0.94"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"178"}],"units":"Participants"}],"title":"Cycle 3 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.19","value":"-1.92"},{"groupId":"OG001","spread":"14.53","value":"0.19"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"156"},{"groupId":"OG001","value":"172"}],"units":"Participants"}],"title":"Cycle 4 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.97","value":"-1.20"},{"groupId":"OG001","spread":"13.75","value":"-0.30"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"166"},{"groupId":"OG001","value":"164"}],"units":"Participants"}],"title":"Cycle 5 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.58","value":"-2.74"},{"groupId":"OG001","spread":"11.09","value":"0.22"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"150"}],"units":"Participants"}],"title":"Cycle 6 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.21","value":"-1.62"},{"groupId":"OG001","spread":"11.95","value":"-0.12"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"144"},{"groupId":"OG001","value":"143"}],"units":"Participants"}],"title":"Cycle 7 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.51","value":"-1.50"},{"groupId":"OG001","spread":"13.33","value":"-0.74"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"133"},{"groupId":"OG001","value":"135"}],"units":"Participants"}],"title":"Cycle 8 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.84","value":"-0.38"},{"groupId":"OG001","spread":"11.10","value":"-0.56"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"118"}],"units":"Participants"}],"title":"Cycle 9 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.48","value":"-0.41"},{"groupId":"OG001","spread":"13.83","value":"0.27"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"123"}],"units":"Participants"}],"title":"Cycle 10 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.91","value":"-1.52"},{"groupId":"OG001","spread":"12.31","value":"-0.56"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"118"}],"units":"Participants"}],"title":"Cycle 11 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.79","value":"-1.09"},{"groupId":"OG001","spread":"13.27","value":"0.15"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"113"}],"units":"Participants"}],"title":"Cycle 12 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.22","value":"-1.62"},{"groupId":"OG001","spread":"17.17","value":"-0.34"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"99"}],"units":"Participants"}],"title":"Cycle 13 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.68","value":"-0.84"},{"groupId":"OG001","spread":"14.82","value":"1.43"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"105"}],"units":"Participants"}],"title":"Cycle 14 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.75","value":"-1.04"},{"groupId":"OG001","spread":"12.29","value":"-0.67"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"100"}],"units":"Participants"}],"title":"Cycle 15 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.28","value":"-1.18"},{"groupId":"OG001","spread":"14.19","value":"-0.90"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"93"}],"units":"Participants"}],"title":"Cycle 16 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.11","value":"1.05"},{"groupId":"OG001","spread":"18.54","value":"0.99"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"84"}],"units":"Participants"}],"title":"Cycle 17 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.54","value":"-0.49"},{"groupId":"OG001","spread":"13.27","value":"0.95"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"title":"Cycle 18 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.35","value":"1.08"},{"groupId":"OG001","spread":"18.17","value":"3.11"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"59"}],"units":"Participants"}],"title":"Cycle 19 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.81","value":"-1.57"},{"groupId":"OG001","spread":"15.56","value":"2.17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"46"}],"units":"Participants"}],"title":"Cycle 20 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.00","value":"0.00"},{"groupId":"OG001","spread":"17.12","value":"2.63"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"38"}],"units":"Participants"}],"title":"Cycle 21 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.48","value":"1.45"},{"groupId":"OG001","spread":"16.38","value":"3.03"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"33"}],"units":"Participants"}],"title":"Cycle 22 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.91","value":"2.78"},{"groupId":"OG001","spread":"9.28","value":"1.72"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"29"}],"units":"Participants"}],"title":"Cycle 23 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.08","value":"-0.44"},{"groupId":"OG001","spread":"6.34","value":"2.78"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"title":"Cycle 24 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.77","value":"-0.54"},{"groupId":"OG001","spread":"6.57","value":"0.83"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"20"}],"units":"Participants"}],"title":"Cycle 25 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.04","value":"0.00"},{"groupId":"OG001","spread":"13.43","value":"4.39"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"title":"Cycle 26 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.65","value":"-0.83"},{"groupId":"OG001","spread":"8.23","value":"1.28"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"title":"Cycle 27 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.67","value":"-2.22"},{"groupId":"OG001","spread":"5.27","value":"1.67"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"title":"Cycle 28 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.01","value":"0.00"},{"groupId":"OG001","spread":"5.27","value":"1.67"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"title":"Cycle 29 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.96","value":"-2.78"},{"groupId":"OG001","spread":"6.30","value":"2.38"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"title":"Cycle 30 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.26","value":"1.69"},{"groupId":"OG001","spread":"16.70","value":"-1.33"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"100"}],"units":"Participants"}],"title":"EOT"}],"denoms":[{"counts":[{"groupId":"OG000","value":"188"},{"groupId":"OG001","value":"200"}],"units":"Participants"}],"description":"EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \\[5 items\\], role \\[2 items\\], emotional \\[4 items\\], cognitive \\[2 items\\], social \\[2 items\\]), symptom scales (fatigue \\[3 items\\], nausea \\& vomiting \\[2 items\\], pain \\[2 items\\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For symptom scales: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for symptoms and a positive change from baseline represents a higher level of symptomatology. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received isatuximab 10 mg/kg IV infusion QW (i.e. on Days 1, 8, 15 and 22) in Cycle 1 (28 days) and then 10 mg/kg Q2W (i.e. on Days 1 and 15) of each subsequent 28-day cycle along with pomalidomide 4 mg orally on Days 1 to 21 of each 28-day cycle and dexamethasone 40 mg (or 20 mg for participant \\>=75 years) orally on Days 1, 8, 15, and 22 of each cycle until disease progression, unacceptable AEs, participant request to discontinue treatment, or any other reason, whichever came first.","id":"OG000","title":"Isa-IV + Pd"},{"description":"Participants received isatuximab 1400 mg SC injection administered via an OBDS which is an investigational device injector QW (i.e on Days 1, 8, 15 and 22) in Cycle 1 (28 days) and then 1400 mg Q2W (i.e. on Days 1 and 15) of each subsequent 28-day cycle along with pomalidomide 4 mg orally on Days 1 to 21 of each 28-day cycle and dexamethasone 40 mg (or 20 mg for participant \\>=75 years) orally on Days 1, 8, 15, and 22 of each cycle until disease progression, unacceptable AEs, participant request to discontinue treatment, or any other reason, whichever came first.","id":"OG001","title":"Isa-SC + Pd"}],"paramType":"MEAN","populationDescription":"The ITT population included all randomized population. Only those participants with data collected at specified timepoints are reported.","reportingStatus":"POSTED","timeFrame":"Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)","title":"Change From Baseline in EORTC QLQ-C30: Nausea and Vomiting","type":"SECONDARY","unitOfMeasure":"score on a scale"}